3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Other
4
Lymphoid
2
Plasma cell
1
Myeloid
1
Gynecologic
1
Classical hematology
1
Conditions
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Azacitidine
68
nilotinib
50
Imatinib Mesylate
50
ruxolitinib
42
Dasatinib
25
venetoclax
22
Decitabine
20
bosutinib
18
asciminib
17
Cytarabine
15
ponatinib
10
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
9
fludarabine
8
Hydroxyurea
8
navitoclax
6
ON 01910
6
sabatolimab
5
pevonedistat
5
mocetinostat
5
luspatercept
5
itacitinib
5
imetelstat
5
givinostat hydrochloride
5
givinostat
5
fludarabine phosphate
5
avapritinib
5
Mycophenolic Acid
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
angiotensin I (1-7)
×
Myeloid
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled